<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143388</url>
  </required_header>
  <id_info>
    <org_study_id>CCRT-AC-LAHR-NPC</org_study_id>
    <nct_id>NCT02143388</nct_id>
  </id_info>
  <brief_title>Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial</brief_title>
  <official_title>Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhao Chong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an randomized controlled, multicenter clinical trial. The purpose of this study is to&#xD;
      evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without&#xD;
      capecitabine as adjuvant chemotherapy in local advanced high risk nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">July 2021</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>18 months</time_frame>
    <description>Defined as the time in months from first dose of cisplatin until PD is observed or death occurs due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the acute toxicity with CTC 3.0 when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Three-year locoregional relapse free survival rate</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Three-year distance metastasis free survival rate</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Three-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the late toxicity with the RTOG/EORTC criterion when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Local Advanced High Risk Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation + adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT combine with cisplatin concurrent chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMRT combine with cisplatin concurrent chemotherapy</intervention_name>
    <description>Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.</description>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy</intervention_name>
    <description>Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.</description>
    <arm_group_label>Concurrent chemoradiation + adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)&#xD;
&#xD;
          -  Clinical stage III~IVb(UICC 7th)&#xD;
&#xD;
          -  Meet at least one factor below :1 primary tumor SUVmax&gt;10 in 18F-FDG PET/CT;2 primary&#xD;
             tumor volume&gt;30cm3;3 mutiple metastatic cervical lymph node with at least one's short&#xD;
             diameter&gt;4cm; 4 T4N2M0; 5 T1-4N3M0;6 EBV-DNA&gt;2×10E4 copy/l&#xD;
&#xD;
          -  Range from 18～70 years old&#xD;
&#xD;
          -  WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L&#xD;
&#xD;
          -  ALT or AST &lt; 2.5×ULN、bilirubin &lt; 1.5×ULN&#xD;
&#xD;
          -  OSerum creatinine &lt; 1.5×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system metastases&#xD;
&#xD;
          -  Suitable for local treatment&#xD;
&#xD;
          -  Uncontrolled seizure disorder or other serious neurologic disease&#xD;
&#xD;
          -  Clinically significant cardiac or respiratory disease&#xD;
&#xD;
          -  Drug or alcohol addition&#xD;
&#xD;
          -  Do not have full capacity for civil acts&#xD;
&#xD;
          -  Severe complication, active infection&#xD;
&#xD;
          -  Concurrent immunotherapy or hormone therapy for other diseases&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhao chong, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Local advanced</keyword>
  <keyword>high risk</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

